AlphaMark Advisors’s Niagen Bioscience NAGE Stock Holding History

AlphaMark Advisors’s Portfolio NAGE Stock Details NAGE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	$4K	Hold	667	–	–	﹤0.01%	540
2024 Q3	$2K	Hold	667	–	–	﹤0.01%	637
2024 Q2	$2K	Hold	667	–	–	﹤0.01%	686
2024 Q1	$2K	Hold	667	–	–	﹤0.01%	673
2023 Q4	$1K	Hold	667	–	–	﹤0.01%	705
2023 Q3	$1K	Hold	667	–	–	﹤0.01%	717
2023 Q2	$1K	Hold	667	–	–	﹤0.01%	606
2023 Q1	$1K	Hold	667	–	–	﹤0.01%	600
2022 Q4	$1K	Hold	667	–	–	﹤0.01%	574
2022 Q3	$1K	Hold	667	–	–	﹤0.01%	672
2022 Q2	$1K	Hold	667	–	–	﹤0.01%	615
2022 Q1	$2K	Hold	667	–	–	﹤0.01%	562
2021 Q4	$2K	Hold	667	–	–	﹤0.01%	534
2021 Q3	$4K	Hold	667	–	–	﹤0.01%	495
2021 Q2	$7K	Hold	667	–	–	﹤0.01%	435
2021 Q1	$6K	Hold	667	–	–	﹤0.01%	431
2020 Q4	$3K	Hold	667	–	–	﹤0.01%	460
2020 Q3	$3K	Hold	667	–	–	﹤0.01%	478
2020 Q2	$3K	Hold	667	–	–	﹤0.01%	476
2020 Q1	$2K	Hold	667	–	–	﹤0.01%	486
2019 Q4	$3K	Hold	667	–	–	﹤0.01%	441
2019 Q3	$3K	Hold	667	–	–	﹤0.01%	445
2019 Q2	$3K	Hold	667	–	–	﹤0.01%	462
2019 Q1	$3K	Hold	667	–	–	﹤0.01%	448
2018 Q4	$2K	Hold	667	–	–	﹤0.01%	446
2018 Q3	$3K	Hold	667	–	–	﹤0.01%	463
2018 Q2	$2K	Hold	667	–	–	﹤0.01%	490
2018 Q1	$3K	Hold	667	–	–	﹤0.01%	464
2017 Q4	$4K	Hold	667	–	–	﹤0.01%	444
2017 Q3	$3K	Hold	667	–	–	﹤0.01%	460
2017 Q2	$3K	Hold	667	–	–	﹤0.01%	471
2017 Q1	$2K	Buy	+667	New	+$1.89K	﹤0.01%	468

Other funds holding NAGE

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

TCM

Tieton Capital Management Yakima, Washington $299M AUM 54.55% 1-Year Est. Return

Iconiq Capital San Francisco, California $4.46B AUM 22.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $43.4B AUM 51.29% 1-Year Est. Return

AlphaMark Advisors's NAGE Position: Q4 2024 in Review

AlphaMark Advisors held its Niagen Bioscience (NAGE) position steady in Q4 2024 at 667 shares worth $4K. The position accounts for ﹤0.01% of the portfolio, ranked #540.

AlphaMark Advisors first reported a position in NAGE in Q1 2017 and has held it in 32 quarters since. The position peaked at $7K in Q2 2021. 123 funds tracked by Wall St. Rank hold NAGE as of Q4 2024.

AlphaMark Advisors held 667 shares of Niagen Bioscience worth $4K as of Q4 2024.
AlphaMark Advisors left its Niagen Bioscience share count unchanged in Q4 2024.
Niagen Bioscience made up ﹤0.01% of AlphaMark Advisors's portfolio in Q4 2024, its #540 holding.
AlphaMark Advisors first reported a position in Niagen Bioscience in Q1 2017 and has held it in 32 quarters since.
AlphaMark Advisors's Niagen Bioscience position peaked at $7K in Q2 2021.
123 funds tracked by Wall St. Rank held Niagen Bioscience as of Q4 2024.

Based on AlphaMark Advisors's 13F filing for Q4 2024, filed 21 Jan 2025.